Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Bicurion Therapeutics AB
AB
Active
Org 5594740945
Erik Dahlbergsgatan 11 A
Manufacture of pharmaceutical preparations · NACE 2120
Est. 2024
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
SEK 0
EBITDA margin
—
Equity ratio
97.8%
Financial strength
Net profit 2024
SEK -80K
0 employees
EBITDA — year on year
SEK millions
0M
-0M
-1M
-1M
-1M
0M
2024
Key figures
Annual report 2024
Revenue
SEK 0
—
EBITDA
SEK -80K
—
Net profit
SEK -80K
—
Total assets
SEK 46K
—
Equity
SEK 45K
—
Employees
0
—
Company information
Legal name
Bicurion Therapeutics AB
Org number
5594740945
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
29 februari 2024
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Företaget skall bedriva utveckling och framtagning av nya läkemedel samt därmed förenlig verksamhet.
Contact
Address
Erik Dahlbergsgatan 11 A
Email
magnus.kall@ventures.gu.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Manufacture of pharmaceutical preparations
Companies in Göteborg
All Sweden companies
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2024
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2024
Income statement
SEK thousands
Item
2024
Revenue
0
Staff expenses
—
EBITDA
−80
Depreciation & amort.
−0
EBIT
−80
Net financials
—
Profit before tax
−80
Tax
−0
Net profit
−80
Balance sheet
SEK thousands
Item
2024
Total assets
46
Equity
45
Long-term debt
0
Short-term debt
1
Total debt
1
Financial ratios
5-year trend
EBITDA margin
-8000000.0%
This company
15.8%
Market median
-50633011% vs market
2024
2024
Equity ratio
97.8%
This company
38.2%
Market median
+156% vs market
2024
2024
Return on equity
-177.8%
This company
18.4%
Market median
-1066% vs market
2024
2024
Net profit margin
-8000000.0%
This company
8.1%
Market median
-98765532% vs market
2024
2024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2024
2024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
2024
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-02-01 – 2024-12-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
Name
Role
Member since
Current (4)
JO
Jan Olof Lötvall
Chairman
2024
AH
Anette Helena Lundquist
Deputy Board Member
2024
MG
Mats Göte Uno Persson
Board of Directors
2024
PM
Per Magnus Käll
Board of Directors
2024
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Exocure Sweden AB
Company
99%
99%
2025
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
Jan Lötvall Holding AB
Exocure Sweden AB
Bicurion Therapeutics AB
(this company)
Board network connections
Board members of Bicurion Therapeutics AB also hold positions in
0
other companies.
Person
Role here
Other companies
Jan Olof Lötvall
Chairman
0 companies
Anette Helena Lundquist
Deputy Board Member
0 companies
Mats Göte Uno Persson
Board of Directors
0 companies
Per Magnus Käll
Board of Directors
0 companies